#1 Clinical Trials Search in Europe

4-((3-((5,6-Dihydro-2-(Trifluoromethyl)(1,2,4)Triazolo(1,5-A)Pyrazin-7(8H)-Yl)Carbonyl)-4-Fluorophenyl)Methyl)-1(2H)-Phthalazinone

Fuzuloparib, also known as SHR3162 or Fluzoparib, is a new drug being studied in clinical trials for the treatment of metastatic castration-resistant prostate cancer (mCRPC). This article discusses an ongoing Phase III clinical trial that combines Fuzuloparib with existing treatments to potentially improve outcomes for patients with this advanced form of prostate cancer.

Table of Contents

What is Fuzuloparib?

Fuzuloparib, also known as Fluzoparib or SHR3162, is a new medication being studied for the treatment of metastatic castration-resistant prostate cancer (mCRPC)[1]. It belongs to a class of drugs called PARP inhibitors, which work by interfering with cancer cells’ ability to repair DNA damage[1].

Target Condition: Metastatic Castration-Resistant Prostate Cancer

Metastatic castration-resistant prostate cancer is an advanced form of prostate cancer that has spread to other parts of the body and no longer responds to treatments that lower testosterone levels[1]. This condition is challenging to treat and requires new therapeutic approaches.

How Fuzuloparib Works

Fuzuloparib is being studied in combination with two other medications:

  • Abiraterone acetate: A hormone therapy that further reduces testosterone production
  • Prednisone: A corticosteroid that helps manage side effects and may have anti-cancer properties

This combination therapy aims to attack cancer cells through multiple mechanisms, potentially improving treatment outcomes for patients with mCRPC[1].

Clinical Trial Overview

A large-scale clinical trial is currently underway to evaluate the effectiveness of Fuzuloparib in treating mCRPC. Key aspects of the trial include:

  • Phase III study: This is an advanced stage of clinical research, typically conducted before a drug can be approved for widespread use
  • Multicenter: The study is being conducted at multiple hospitals or research centers
  • Randomized and double-blind: Participants are randomly assigned to either the Fuzuloparib group or a placebo group, and neither the patients nor the researchers know which treatment each participant is receiving
  • Two patient cohorts:
    1. Unselected mCRPC patients
    2. mCRPC patients with specific genetic mutations (DRD-positive)

The main goal of the study is to determine if Fuzuloparib, when combined with abiraterone acetate and prednisone, is more effective than the current standard treatment in slowing disease progression and improving survival rates[1].

Eligibility Criteria

To participate in the clinical trial, patients must meet certain criteria, including:

  • Age 18 or older
  • Confirmed diagnosis of metastatic castration-resistant prostate cancer
  • No prior treatment with PARP inhibitors or certain other cancer therapies
  • Adequate organ function and overall health status
  • Willingness to provide blood and tumor tissue samples for genetic testing

There are also several exclusion criteria, such as certain medical conditions or prior treatments that may interfere with the study results or pose additional risks to participants[1].

Potential Benefits

If successful, Fuzuloparib could offer several potential benefits for mCRPC patients:

  • Improved progression-free survival: The treatment may slow down or stop cancer growth for a longer period
  • Increased overall survival: Patients may live longer with this new combination therapy
  • Targeted treatment: Especially beneficial for patients with specific genetic mutations (DRD-positive)
  • New treatment option: Provides an alternative for patients who have limited choices or have not responded to other therapies

Considerations and Precautions

While Fuzuloparib shows promise, it’s important to note:

  • The drug is still experimental and not yet approved for general use
  • Potential side effects are still being studied
  • Not all patients may be eligible for or benefit from this treatment
  • Long-term effects are not yet known

Patients interested in this treatment should discuss it thoroughly with their healthcare providers to understand the potential risks and benefits in their specific case[1].

Aspect Details
Drug Name Fuzuloparib (SHR3162, Fluzoparib)
Drug Class PARP inhibitor
Condition Treated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Trial Phase Phase III
Trial Design Multicenter, Randomized, Double-Blind, Placebo-Controlled
Treatment Combination Fuzuloparib + Abiraterone Acetate + Prednisone vs. Placebo + Abiraterone Acetate + Prednisone
Primary Endpoint Radiographic Progression-Free Survival (rPFS)
Secondary Endpoint Overall Survival (OS)
Key Eligibility Criteria Adults with mCRPC, no prior mCRPC treatment, ECOG 0-1, castration-level testosterone
Special Considerations Includes cohort of patients with DNA Repair Deficiency (DRD)

FAQ

  • What is Fuzuloparib? Fuzuloparib is a new drug being tested for the treatment of metastatic castration-resistant prostate cancer. It belongs to a class of drugs called PARP inhibitors and is taken orally in capsule form.
  • What is the main goal of this clinical trial? The main goal is to evaluate if Fuzuloparib, when combined with Abiraterone Acetate and Prednisone (AA-P), is more effective than a placebo with AA-P in treating mCRPC as a first-line treatment.
  • Who can participate in this clinical trial? Eligible participants are adults (18 years or older) with confirmed metastatic castration-resistant prostate cancer, who have not received prior treatment for mCRPC, and meet specific health criteria outlined in the study protocol.
  • What are the main outcomes being measured in this trial? The primary outcome is radiographic progression-free survival (rPFS), which measures how long patients live without their cancer growing or spreading. The study also looks at overall survival (OS) as a secondary outcome.
  • Are there any specific genetic factors considered in this trial? Yes, the trial includes a specific group (Cohort 2) of patients who have tumors with DNA repair deficiency (DRD). The study aims to see if Fuzuloparib is particularly effective in this subgroup of patients.

Ongoing Clinical Trials on 4-((3-((5,6-Dihydro-2-(Trifluoromethyl)(1,2,4)Triazolo(1,5-A)Pyrazin-7(8H)-Yl)Carbonyl)-4-Fluorophenyl)Methyl)-1(2H)-Phthalazinone

  • Study of Fuzuloparib, Abiraterone Acetate, and Prednisone for First-Line Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Czechia France Hungary Poland Spain

Glossary

  • Metastatic Castration-Resistant Prostate Cancer (mCRPC): A type of advanced prostate cancer that has spread to other parts of the body and continues to grow despite treatments that lower testosterone levels.
  • PARP inhibitor: A type of drug that blocks an enzyme called poly (ADP-ribose) polymerase, which helps repair DNA damage in cells. By blocking this enzyme, PARP inhibitors may help kill cancer cells.
  • Abiraterone Acetate: A hormone therapy drug used to treat prostate cancer by reducing the production of testosterone in the body.
  • Prednisone: A corticosteroid medication often used in combination with other cancer treatments to reduce inflammation and manage side effects.
  • Radiographic Progression-Free Survival (rPFS): The length of time during and after treatment that a patient lives without their cancer growing or spreading, as determined by imaging tests.
  • Overall Survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • DNA Repair Deficiency (DRD): A condition where cells have difficulty repairing damaged DNA, which can make them more susceptible to certain cancer treatments.
  • ECOG Performance Status: A scale used to assess how a patient's disease affects their daily living abilities and determine appropriate treatment.
  • Androgen Deprivation Therapy: A treatment that reduces levels of male hormones (androgens) in the body to slow the growth of prostate cancer.
  • Bilateral Orchidectomy: A surgical procedure to remove both testicles, which is sometimes used as a form of hormone therapy for prostate cancer.

References

  1. http://clinicaltrials.eu/trial/study-of-fuzuloparib-abiraterone-acetate-and-prednisone-for-first-line-treatment-in-patients-with-metastatic-castration-resistant-prostate-cancer/